Key Highlights

  • Jeffrey Rhodes stepped down from the LifeStance Health board on July 2, 2026 with no disclosed disagreement.

LifeStance Health Group, Inc. (NASDAQ: LFST) disclosed a sudden change to its board composition on July 2, 2026. The filing noted the immediate exit of one director and the addition of three new members, marking a notable shift in governance structure.

Board Resignation Details

The company reported that Jeffrey Rhodes resigned effective immediately, indicating that the departure was not linked to any dispute with the organization. Rhodes’ departure opened three vacancies that were filled on the same day. Justice and Goltermann will hold Class II seats that run through the 2029 annual shareholder meeting, while Shabab will serve as a Class III director until the 2027 meeting.

Goltermann will participate on the compensation committee and the nominating and governance committee. Shabab will sit on the nomination and governance committee. The awards will vest over time and are tied to continued board service.

Term Lengths and Shareholder Meetings

The directors’ service periods are aligned with upcoming shareholder meetings, providing continuity through the 2027 and 2029 cycles. This alignment supports consistent oversight of the company’s strategic initiatives.

Governance Outlook

The refreshed board aims to enhance oversight across key areas such as audit, compensation and compliance. By bringing in new expertise and syncing director terms with future meetings, LifeStance Health anticipates a stable and effective governance environment.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.